Cargando…

4164 Body mass index, not chemotherapy is the major predictor of insulin resistance in patients with hematological malignancies

OBJECTIVES/GOALS: Cancer survivors are at increased risk for type 2 diabetes mellitus.It is not clear if diabetes susceptibility is due to shared risk factors for cancer and diabetes, such as obesity, or if it is directly related to cancer and its treatment. We investigated the association between m...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahinoz, Melis, Engelhardt, Brian, Jung, Dae Kwang, Luther, James Matthew, Ikizler, Talat Alp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823689/
http://dx.doi.org/10.1017/cts.2020.372
_version_ 1784646854098550784
author Sahinoz, Melis
Engelhardt, Brian
Jung, Dae Kwang
Luther, James Matthew
Ikizler, Talat Alp
author_facet Sahinoz, Melis
Engelhardt, Brian
Jung, Dae Kwang
Luther, James Matthew
Ikizler, Talat Alp
author_sort Sahinoz, Melis
collection PubMed
description OBJECTIVES/GOALS: Cancer survivors are at increased risk for type 2 diabetes mellitus.It is not clear if diabetes susceptibility is due to shared risk factors for cancer and diabetes, such as obesity, or if it is directly related to cancer and its treatment. We investigated the association between malignancy and insulin resistance, a major risk factor for diabetes. METHODS/STUDY POPULATION: 20 adult patients with treated hematological malignancies and 21 controls without cancer were included in the study. Individuals with pre-existing diabetes were excluded. All patients underwent a 2-hour 75-gram oral glucose tolerance test (OGTT). Hyperinsulinemic-euglycemic clamps were performed to measure the steady-state glucose infusion rate (M-value) as an indicator of whole-body glucose utilization during insulin stimulation. Insulin sensitivity index was calculated by dividing M-value over the steady-state plasma insulin (M/I). RESULTS/ANTICIPATED RESULTS: Fasting or postprandial plasma glucose levels during the OGTT did not differ significantly between malignancy patients and controls (Table 2). Difference in the insulin-stimulated glucose utilization (M-value) was not statistically significant among cancer patients and controls (median, 7.2 [IQR, 6.2-10.4] vs. 7.3 [IQR, 5.5-8.9] mg/kg/min; P = 0.261). M/I index was significantly higher in malignancy patients compared to controls (median, 42.4 mg/kg/min/(µU/ml) [IQR, 33.9-67.2] vs. 23.4 mg/kg/min/(µU/ml) [IQR, 12.9-29.2], P <0.001), however insulin clearance was also lower in the controls. In multivariate analysis, only BMI was significantly associated with M-value (β = −0.2 (95% CI −0.4, −0.1), P = 0.004), and M/I (β = −2 (95% CI −3.4, −0.5), P = 0.009). DISCUSSION/SIGNIFICANCE OF IMPACT: Our data suggest that the major contributor to diabetes development after diagnosis of cancer in adults is obesity-induced insulin resistance, not malignancy related factors. These findings emphasize the importance of obesity management in long-term survival of cancer patients, as diabetes is a risk factor for mortality in this patient population.
format Online
Article
Text
id pubmed-8823689
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-88236892022-02-18 4164 Body mass index, not chemotherapy is the major predictor of insulin resistance in patients with hematological malignancies Sahinoz, Melis Engelhardt, Brian Jung, Dae Kwang Luther, James Matthew Ikizler, Talat Alp J Clin Transl Sci Translational Science, Policy, & Health Outcomes Science OBJECTIVES/GOALS: Cancer survivors are at increased risk for type 2 diabetes mellitus.It is not clear if diabetes susceptibility is due to shared risk factors for cancer and diabetes, such as obesity, or if it is directly related to cancer and its treatment. We investigated the association between malignancy and insulin resistance, a major risk factor for diabetes. METHODS/STUDY POPULATION: 20 adult patients with treated hematological malignancies and 21 controls without cancer were included in the study. Individuals with pre-existing diabetes were excluded. All patients underwent a 2-hour 75-gram oral glucose tolerance test (OGTT). Hyperinsulinemic-euglycemic clamps were performed to measure the steady-state glucose infusion rate (M-value) as an indicator of whole-body glucose utilization during insulin stimulation. Insulin sensitivity index was calculated by dividing M-value over the steady-state plasma insulin (M/I). RESULTS/ANTICIPATED RESULTS: Fasting or postprandial plasma glucose levels during the OGTT did not differ significantly between malignancy patients and controls (Table 2). Difference in the insulin-stimulated glucose utilization (M-value) was not statistically significant among cancer patients and controls (median, 7.2 [IQR, 6.2-10.4] vs. 7.3 [IQR, 5.5-8.9] mg/kg/min; P = 0.261). M/I index was significantly higher in malignancy patients compared to controls (median, 42.4 mg/kg/min/(µU/ml) [IQR, 33.9-67.2] vs. 23.4 mg/kg/min/(µU/ml) [IQR, 12.9-29.2], P <0.001), however insulin clearance was also lower in the controls. In multivariate analysis, only BMI was significantly associated with M-value (β = −0.2 (95% CI −0.4, −0.1), P = 0.004), and M/I (β = −2 (95% CI −3.4, −0.5), P = 0.009). DISCUSSION/SIGNIFICANCE OF IMPACT: Our data suggest that the major contributor to diabetes development after diagnosis of cancer in adults is obesity-induced insulin resistance, not malignancy related factors. These findings emphasize the importance of obesity management in long-term survival of cancer patients, as diabetes is a risk factor for mortality in this patient population. Cambridge University Press 2020-07-29 /pmc/articles/PMC8823689/ http://dx.doi.org/10.1017/cts.2020.372 Text en © The Association for Clinical and Translational Science 2020 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Translational Science, Policy, & Health Outcomes Science
Sahinoz, Melis
Engelhardt, Brian
Jung, Dae Kwang
Luther, James Matthew
Ikizler, Talat Alp
4164 Body mass index, not chemotherapy is the major predictor of insulin resistance in patients with hematological malignancies
title 4164 Body mass index, not chemotherapy is the major predictor of insulin resistance in patients with hematological malignancies
title_full 4164 Body mass index, not chemotherapy is the major predictor of insulin resistance in patients with hematological malignancies
title_fullStr 4164 Body mass index, not chemotherapy is the major predictor of insulin resistance in patients with hematological malignancies
title_full_unstemmed 4164 Body mass index, not chemotherapy is the major predictor of insulin resistance in patients with hematological malignancies
title_short 4164 Body mass index, not chemotherapy is the major predictor of insulin resistance in patients with hematological malignancies
title_sort 4164 body mass index, not chemotherapy is the major predictor of insulin resistance in patients with hematological malignancies
topic Translational Science, Policy, & Health Outcomes Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8823689/
http://dx.doi.org/10.1017/cts.2020.372
work_keys_str_mv AT sahinozmelis 4164bodymassindexnotchemotherapyisthemajorpredictorofinsulinresistanceinpatientswithhematologicalmalignancies
AT engelhardtbrian 4164bodymassindexnotchemotherapyisthemajorpredictorofinsulinresistanceinpatientswithhematologicalmalignancies
AT jungdaekwang 4164bodymassindexnotchemotherapyisthemajorpredictorofinsulinresistanceinpatientswithhematologicalmalignancies
AT lutherjamesmatthew 4164bodymassindexnotchemotherapyisthemajorpredictorofinsulinresistanceinpatientswithhematologicalmalignancies
AT ikizlertalatalp 4164bodymassindexnotchemotherapyisthemajorpredictorofinsulinresistanceinpatientswithhematologicalmalignancies